Prospective patient preference study for Bruton tyrosine kinase inhibitor (BTKi) treatment attributes and factors affecting patient shared decision-making in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in the United States (US)
Expert Review of Hematology | January 13, 2026 | Volume: 19 | Issue: 3 | Pages: 321-331
10.1080/17474086.2026.2617270
| PMID 41528878